Risk vs Reward – The Story Of Valeant And Sequoia Fund

Risk vs Reward – The Story Of Valeant And Sequoia Fund

Risk vs Reward – The Story Of Valeant And Sequoia Fund by Ben Strubel, Strubel Investment Management

There’s no shame in being a little bit above average. The goal of many hedge fund managers and value investors is to outperform the market by as much as possible. It’s not uncommon for hedge fund managers to target returns of 15% per year or more. (Keep in mind, the stock market returns 10% on average.) The only way to get extreme out-performance is to hold extreme portfolios.

By definition, to outperform the market, your portfolio must be different from the market. The greater the out-performance you want, the greater the difference needs to be. Take the S&P 500 for instance, an index of 500 of the largest US stocks. If you put together a portfolio of 450 stocks, you’d have a difficult time trying to beat the index because your portfolio closely resembles the index. Now imagine you had a portfolio of just three stocks. That portfolio would perform vastly different from the index. You’d have a much better chance of beating the index with a portfolio of just a few stocks.

Depending on what you picked, however, the difference could be worse or better. For instance, if you picked a portfolio of just Amazon (AMZN), Google (GOOGL) [I don’t care they changed their name to Alphabet, they’ll always be Google to me], and Facebook (FB), then you would be killing the market this year. Conversely, if you picked a portfolio of just Exxon Mobil (XOM), Wal-Mart (WMT), and Caterpillar (CAT), then you would have lost a substantial amount of money.

Baupost’s Seth Klarman Suggests That The U.S. Could Be Uninvestable One Day

Seth KlarmanIn his 2021 year-end letter, Baupost's Seth Klarman looked at the year in review and how COVID-19 swept through every part of our lives. He blamed much of the ills of the pandemic on those who choose not to get vaccinated while also expressing a dislike for the social division COVID-19 has caused. Q4 2021 Read More

My goal for most clients is a lot more modest than the average hedge fund manager. I’d like to outperform the markets by 1 or 2% per year after fees—nothing too crazy. If you think 1% or 2% doesn’t sound like a lot, remember it compounds over time so it ends up being substantial. The reason why I have a much more modest target has to do with risk management. My first and foremost goal for clients is risk management and not to blow up their portfolios in spectacular fashion.

I don’t care how great an investor you are, the world is a crazy, random place and everyone misses something every now and then. No one is perfect. Nothing illustrates the folly of improper diversification quite like the story of Valeant Pharmaceuticals (VRX). We wrote about Valeant in our last newsletter, so if you want to know more about what is going on with that company you can read about that here.

Many previously successful fund managers put a huge portion of their clients’ assets in Valeant. The Sequoia Fund (SEQUX), a mutual fund that Warren Buffett had recommended in the past, put around 30% of the fund into Valeant stock. I can’t emphasize this enough: They put almost a third of their clients’ money in just one company! Many other famous, successful investors, such as Bill Ackman of Pershing Square, John Paulson of betting-against-subprime-mortgage fame, and Jeff Ubben of ValueAct Capital, had huge stakes in the company (often close to 10% of their funds).

While the ultimate fate of Valeant is still unknown, there is and was ample evidence that something was just not quite right at the company. The business model made no sense, and now it appears the company may have issues with inventory building up in some European distribution channels. And there are more questions about just how widespread the “creative” insurance billing practices of their captive specialty pharmacies were. All investing involves risk, and everyone makes mistakes so I’m not criticizing any of those aforementioned fund managers for taking a chance on what was marketed as an exciting, growing, innovative pharmaceutical company. What I am saying is that a company with so many unknowns and with some many potential pitfalls shouldn’t make up such a large part of your portfolio.

This topic also relates to my next one. After years of telling everyone interest rate hikes were just around the corner, the Federal Reserve looks like it will actually raise interest rates at the end of this year or the beginning of 2016. Additionally, the recent budget deal passed by Congress should provide enough fiscal stimuli to allow the Fed to continue gradually to raise rates perhaps throughout 2017. The wild card in everything is the strength of the dollar. If the dollar continues to gain, then it will slow exports and increase imports (widening the trade deficit). A widening trade deficit would have a negative impact on the economy, and it might be enough to offset some of the minor fiscal stimulus we will see from the new budget deal. In any case, we are closer to the beginning of interest rates being raised than we have ever been.

With interest rates going up, it may finally be time to invest in the financial sector. Since the financial crisis, the financial sector has underperformed as low interest rates have hurt banks profitability. (I won’t get into all the gory details here.) However, things look like they are finally starting to change. Therefore, we are starting to look at investing in financial companies. Nevertheless, there is one problem.

The financial sector is probably one of the most difficult to analyze. For example, Citigroup’s last 10-K was 306 pages long compared to Altria Group’s 114-page 10-K. Now add into this the fact that it seems like every single big bank is part bank and part criminal organization. That adds another degree of difficulty to the equation. Banks have been investigated and “found guilty” (well, they usually are never actually forced to admit guilt) of numerous crimes and civil infractions and paid out more than $180B in fines since the financial crisis.

In an effort to take advantage of a rising Fed funds rate, which should benefit financial institutions, and also to avoid becoming the next Sequoia Fund, we are considering investing in a financial sector ETF. That way we won’t have a Valeant Pharmaceuticals situation on our hands with client portfolios having a concentrated position in a single financial institution with the risk something catastrophic happening to that company. We’d rather manage risk properly and settle for “just” being above average.

No Company Profiled

No Company Profiled This Month.

About Our Portfolios

The Capital Appreciation Fund and the Dividend Fund are innovative, investor friendly alternative to traditional actively managed mutual funds called a Spoke Fund ®. We can also customize portfolios for clients seeking less risk and volatility by including allocations to other asset classes such as bonds and real estate.

Spoke Funds are significantly less expensive and more transparent than a large majority of mutual funds. Both portfolios are managed for the long term using value investing principles. Fees for both portfolios are 1.25% of assets annually. That figure includes both our management fee and all trading costs. We try to minimize turnover and taxes as well in both funds.

Investor accounts are held in your name (we never take investor money) at FOLIOfn or Interactive Brokers*.

For more information visit our website.

*Some older accounts may be custodied at TradePMR.


Historical results are not indicative of future performance. Positive returns are not guaranteed. Individual results will vary depending on market conditions and investing may cause capital loss.

The performance data presented prior to 2011:

  •  Represents a composite of all discretionary equity investments in accounts that have been open for at least one year. Any accounts open for less than one year are excluded from the composite performance shown. From time to time clients have made special requests that SIM hold securities in their account that are not included in SIMs recommended equity portfolio, those investments are excluded from the composite results shown.
  • Performance is calculated using a holding period return formula.
  • Reflect the deduction of a management fee of 1% of assets per year.
  • Reflect the reinvestment of capital gains and dividends.

Performance data presented for 2011 and after:

  • Represents the performance of the model portfolio that client accounts are linked too.
  • Reflect the deduction of management fees of 1% of assets per year.
  • Reflect the reinvestment of capital gains and dividends.

The S&P 500, used for comparison purposes may have a significantly different volatility than the portfolios used for the presentation of SIM’s composite returns.

The publication of this performance data is in no way a solicitation or offer to sell securities or investment advisory services.

Updated on

Ben Strubel earned a Master’s in Business Administration in Investment Management from Drexel University’s LeBow College of Business in Philadelphia, PA. He was inducted into the Beta Gamma Sigma honor society, the highest academic honor society for master’s degree students. While at Drexel, Mr. Strubel founded the LeBow Graduate Investment Management Club and the DragonFund Large-Cap Fund, which was responsible for investing $250,000 of Drexel University’s endowment. He also holds a Graduate Certificate in Financial Planning from Florida State University. He earned a B.S. in Information Technology from Rochester Institute of Technology in Rochester, NY. He teaches classes on finance and investing at Harrisburg Area Community College and for Manheim Township. Mr. Strubel also writes for several investing websites including Valuewalk.com and SeekingAlpha.com. He resides in Lancaster, PA.
Previous article What The IMF’s Yuan Decision Will Mean For China – And Global Markets
Next article Russia’s ISIS Claims Do Little To Dent Turkey

No posts to display